Cabral FV et al., 2024-06-24: Study using wearable OLED light sources with the methylene blue derivative 1,9-dimethyl methylene blue against miltefosine-resistant Leishmania amazonensis in vitro and in mice: EC50 0.034 micromolar against promastigotes of both the resistant and wild-type strains, and 0.052 and 0.077 micromolar against amastigotes.
The in vitro activity of OLEDs combined with 1,9-dimethyl-methylene blue (DMMB) (OLED-PDT) was evaluated against wild-type and miltefosine-resistant L. amazonensis strains in promastigote (EC50 = 0.034 μM for both strains) and amastigote forms (EC50 = 0.052 μM and 0.077 μM, respectively).
Abstract
Cabral FV et al., 2024-06-24: Study using wearable OLED light sources with the methylene blue derivative 1,9-dimethyl methylene blue against miltefosine-resistant Leishmania amazonensis in vitro and in mice: EC50 0.034 micromolar against promastigotes of both the resistant and wild-type strains, and 0.052 and 0.077 micromolar against amastigotes. Study type: in vitro plus animal (mouse L. amazonensis lesion model). Countries: Brazil and UK (University of St Andrews). Photosensitiser: 1,9-dimethyl methylene blue (a methylene blue derivative, not methylene blue itself) with OLED light; EC50 0.034 uM promastigotes, 0.052-0.077 uM amastigotes. Conflicts (declared): 'I.D.W.S. is a founder and shareholder of Lustre Skin Ltd, which develops wearable light sources for the treatment of acne.' Relevance: resistance-breaking in the laboratory, not a human result. Study type: animal.
